Ipsen Biopharmaceuticals, Inc.

IPSEY

$12.89B

Large Cap

NASDAQHealthcare🇺🇸North America5.4K employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 19, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

11 upcoming, 0 past

⭐Phase 3Next

Elafibranor Phase 3 Results Expected

Mar 19, 2026Elafibranor18

Primary completion for Elafibranor trial (NCT06730061) in Primary Biliary Cholangitis

Source

⭐Phase 3

Botulinum toxin type A Phase 3 Results Expected

Jun 5, 2026Botulinum toxin type A759

Primary completion for Botulinum toxin type A trial (NCT06047457) in Episodic Migraine

Source

⭐Phase 3

Odevixibat Phase 3 Results Expected

Jun 26, 2026Odevixibat254

Primary completion for Odevixibat trial (NCT04336722) in Biliary Atresia

Source

⭐Phase 3

Elafibranor Phase 3 Results Expected

Jun 26, 2026Elafibranor69

Primary completion for Elafibranor trial (NCT06383403) in Primary Biliary Cholangitis

Source

⭐Phase 3

Placebo Phase 3 Results Expected

Jun 26, 2026Botulinum toxin type A254

Primary completion for Placebo trial (NCT04336722) in Biliary Atresia

Source

Phase 2

Elafibranor 80 mg Phase 2 Results Expected

Aug 28, 2026Elafibranor 80 mg68

Primary completion for Elafibranor 80 mg trial (NCT05627362) in Primary Sclerosing Cholangitis

Source

Phase 2

IPN10200 Phase 2 Results Expected

Aug 31, 2026IPN10200727

Primary completion for IPN10200 trial (NCT04821089) in Moderate to Severe Upper Facial Lines

Source

Phase 2

Dysport Phase 2 Results Expected

Aug 31, 2026Dysport727

Primary completion for Dysport trial (NCT04821089) in Moderate to Severe Upper Facial Lines

Source

Phase 2

Cabozantinib Phase 2 Results Expected

Oct 26, 2026Cabozantinib10

Primary completion for Cabozantinib trial (NCT06341712) in Osteosarcoma

Source

⭐Phase 3

Elafibranor Phase 3 Results Expected

Dec 17, 2026Elafibranor18

Primary completion for Elafibranor trial (NCT06730061) in Primary Biliary Cholangitis

Source

⭐Phase 3

Odevixibat Phase 3 Results Expected

Dec 31, 2026Odevixibat70

Primary completion for Odevixibat trial (NCT05035030) in Alagille Syndrome

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

BLI800

Phase 3

Diagnosis Disease

Odevixibat

Phase 3

Biliary Atresia

Lanreotide autogel 120 mg

Phase 3

Acromegaly

Lanreotide (microparticle formulation)

Phase 3

Intestinal Obstruction

Somatuline Autogel (lanreotide acetate)

Phase 3

Acromegaly

Triptorelin Pamoate 11.25mg

Phase 3

Prostate Cancer

lanreotide (Autogel formulation), duration of treatment 46-48 weeks

Phase 3

Acromegaly

Irinotecan liposome injection

Phase 3

Small Cell Lung Cancer

Triptorelin (Decapeptyl®)

Phase 3

Prostate Cancer

Palovarotene

Phase 3

Fibrodysplasia Ossificans Progressiva (FOP)

Smecta (Diosmectite), duration of treatment - 7 days

Phase 3

Diarrhoea

Triptorelin Pamoate

Phase 3

Central Precocious Puberty

Lanreotide Autogel

Phase 3

Intestinal Obstruction

EGb 761® (Tanakan®)

Phase 3

Multiple Sclerosis, Relapsing-Remitting

Lanreotide (Autogel formulation)

Phase 3

Acromegaly

Lanreotide Autogel®

Phase 3

Acromegaly

PEG 4000 (Forlax®)

Phase 3

Chronic Constipation

Triptorelin embonate 22.5 mg

Phase 3

Prostate Cancer

Triptorelin Pamoate PR 3-month

Phase 3

Endometriosis

A4250 (odevixibat)

Phase 3

Progressive Familial Intrahepatic Cholestasis

Pegvisomant

Phase 3

Acromegaly

Elafibranor 80mg

Phase 3

Primary Biliary Cirrhosis

rhIGF-1 (mecasermin, Tercica, Inc.)

Phase 3

Growth Disorders

Irinotecan Liposomal Injection

Phase 3

Metastatic Adenocarcinoma of the Pancreas

Eziclen®/Izinova®

Phase 3

Digestive System Disease

Triptorelin pamoate (embonate) salt

Phase 3

Advanced Prostate Cancer

Elafibranor

Phase 3

Primary Biliary Cholangitis

lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval

Phase 3

Acromegaly

Triptorelin pamoate 11.25mg (Decapeptyl® SR)

Phase 3

Precocious Puberty

Botulinum toxin type A

Phase 3

Glabellar Frown Lines

Triptorelin (I.N.N.)

Phase 3

Precocious Puberty

EGb761

Phase 3

Stroke, Acute

mecasermin

Phase 3

Growth Hormone Insensitivity Syndrome

Eziclen

Phase 3

Bowel Cleansing

rhIGF-1 (mecasermin) for a period of 86 weeks

Phase 3

Insulin-Like Growth Factor-1 Deficiency

Lanreotide

Phase 3

Carcinoid Syndrome

Triptorelin pamoate 15mg

Phase 3

Central Precocious Puberty

Lanreotide microparticles

Phase 3

Digestive Fistulae

Somatropin (rDNA origin)

Phase 3

Turner Syndrome

Lanreotide PRF

Phase 2

Acromegaly

EGb761®

Phase 2

Alzheimer's Disease

IPN01195

Phase 2

Advanced Solid Tumor

nal-IRI

Phase 2

Pancreatic Cancer

IPN60300

Phase 2

Locally Advanced Solid Tumor

IPN01203

Phase 2

Advanced Solid Tumor

Elafibranor 80 mg

Phase 2

Primary Sclerosing Cholangitis

IPN10200

Phase 2

Moderate to Severe Upper Facial Lines

Cabozantinib

Phase 2

Locally Advanced or Metastatic Renal Cell Carcinoma

Triptorelin Pamoate (Pamorelin® LA 11.25 mg)

Phase 2

Prostate Cancer

BN83495

Phase 2

Endometrial Cancer

Lidocaine

Phase 2

Chronic Scar Pain

satoreotide trizoxetan

Phase 2

Gastroenteropancreatic Neuroendocrine Tumors

Dysport

Phase 2

Spasticity

IPN01194

Phase 2

Melanoma

Ritivixibat

Phase 2

Primary Sclerosing Cholangitis

Temozolomide (TMZ)

Phase 2

Gastroenteropancreatic Neuroendocrine Tumors

Tasquinimod

Phase 2

Advanced or Metastatic Hepatocellular Cancer

Lanreotide (Autogel formulation) and Temozolomide

Phase 2

Neuroendocrine Tumours

Diflomotecan (BN80915)

Phase 2

Small Cell Lung Cancer

EGb 761 120 mg

Phase 2

Friedreich Ataxia

IPN10200 dose A

Phase 2

Episodic Migraine

Satoreotide trizoxetan 5-20μg

Phase 2

Gastro-Enteropancreatic Neuroendocrine Tumor

Drug Name	Phase	Indication	Designations
BLI800	Phase 3	Diagnosis Disease	-
Odevixibat	Phase 3	Biliary Atresia	-
Lanreotide autogel 120 mg	Phase 3	Acromegaly	-
Lanreotide (microparticle formulation)	Phase 3	Intestinal Obstruction	-
Somatuline Autogel (lanreotide acetate)	Phase 3	Acromegaly	-
Triptorelin Pamoate 11.25mg	Phase 3	Prostate Cancer	-
lanreotide (Autogel formulation), duration of treatment 46-48 weeks	Phase 3	Acromegaly	-
Irinotecan liposome injection	Phase 3	Small Cell Lung Cancer	-
Triptorelin (Decapeptyl®)	Phase 3	Prostate Cancer	-
Palovarotene	Phase 3	Fibrodysplasia Ossificans Progressiva (FOP)	-
Smecta (Diosmectite), duration of treatment - 7 days	Phase 3	Diarrhoea	-
Triptorelin Pamoate	Phase 3	Central Precocious Puberty	-
Lanreotide Autogel	Phase 3	Intestinal Obstruction	-
EGb 761® (Tanakan®)	Phase 3	Multiple Sclerosis, Relapsing-Remitting	-
Lanreotide (Autogel formulation)	Phase 3	Acromegaly	-
Lanreotide Autogel®	Phase 3	Acromegaly	-
PEG 4000 (Forlax®)	Phase 3	Chronic Constipation	-
Triptorelin embonate 22.5 mg	Phase 3	Prostate Cancer	-
Triptorelin Pamoate PR 3-month	Phase 3	Endometriosis	-
A4250 (odevixibat)	Phase 3	Progressive Familial Intrahepatic Cholestasis	-
Pegvisomant	Phase 3	Acromegaly	-
Elafibranor 80mg	Phase 3	Primary Biliary Cirrhosis	-
rhIGF-1 (mecasermin, Tercica, Inc.)	Phase 3	Growth Disorders	-
Irinotecan Liposomal Injection	Phase 3	Metastatic Adenocarcinoma of the Pancreas	-
Eziclen®/Izinova®	Phase 3	Digestive System Disease	-
Triptorelin pamoate (embonate) salt	Phase 3	Advanced Prostate Cancer	-
Elafibranor	Phase 3	Primary Biliary Cholangitis	-
lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval	Phase 3	Acromegaly	-
Triptorelin pamoate 11.25mg (Decapeptyl® SR)	Phase 3	Precocious Puberty	-
Botulinum toxin type A	Phase 3	Glabellar Frown Lines	-
Triptorelin (I.N.N.)	Phase 3	Precocious Puberty	-
EGb761	Phase 3	Stroke, Acute	-
mecasermin	Phase 3	Growth Hormone Insensitivity Syndrome	-
Eziclen	Phase 3	Bowel Cleansing	-
rhIGF-1 (mecasermin) for a period of 86 weeks	Phase 3	Insulin-Like Growth Factor-1 Deficiency	-
Lanreotide	Phase 3	Carcinoid Syndrome	-
Triptorelin pamoate 15mg	Phase 3	Central Precocious Puberty	-
Lanreotide microparticles	Phase 3	Digestive Fistulae	-
Somatropin (rDNA origin)	Phase 3	Turner Syndrome	-
Lanreotide PRF	Phase 2	Acromegaly	-
EGb761®	Phase 2	Alzheimer's Disease	-
IPN01195	Phase 2	Advanced Solid Tumor	-
nal-IRI	Phase 2	Pancreatic Cancer	-
IPN60300	Phase 2	Locally Advanced Solid Tumor	-
IPN01203	Phase 2	Advanced Solid Tumor	-
Elafibranor 80 mg	Phase 2	Primary Sclerosing Cholangitis	-
IPN10200	Phase 2	Moderate to Severe Upper Facial Lines	-
Cabozantinib	Phase 2	Locally Advanced or Metastatic Renal Cell Carcinoma	-
Triptorelin Pamoate (Pamorelin® LA 11.25 mg)	Phase 2	Prostate Cancer	-
BN83495	Phase 2	Endometrial Cancer	-
Lidocaine	Phase 2	Chronic Scar Pain	-
satoreotide trizoxetan	Phase 2	Gastroenteropancreatic Neuroendocrine Tumors	-
Dysport	Phase 2	Spasticity	-
IPN01194	Phase 2	Melanoma	-
Ritivixibat	Phase 2	Primary Sclerosing Cholangitis	-
Temozolomide (TMZ)	Phase 2	Gastroenteropancreatic Neuroendocrine Tumors	-
Tasquinimod	Phase 2	Advanced or Metastatic Hepatocellular Cancer	-
Lanreotide (Autogel formulation) and Temozolomide	Phase 2	Neuroendocrine Tumours	-
Diflomotecan (BN80915)	Phase 2	Small Cell Lung Cancer	-
EGb 761 120 mg	Phase 2	Friedreich Ataxia	-
IPN10200 dose A	Phase 2	Episodic Migraine	-
Satoreotide trizoxetan 5-20μg	Phase 2	Gastro-Enteropancreatic Neuroendocrine Tumor	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

IPSEY News